A.T.S.

Advanced Targeting Systems (ATS) is a biotechnology company specializing in "Molecular Surgery," a technique that uses targeted toxins to selectively eliminate specific cell populations. The company's core technology involves conjugating the ribosome-inactivating protein saporin to antibodies, ligands, or peptides that target specific cell-surface receptors. While primarily recognized as a leading provider of research reagents and custom conjugation services for neuroscience and drug discovery, ATS has also advanced its own internal pipeline of therapeutic candidates. Their lead program, SP-SAP, has been evaluated in clinical trials for the treatment of chronic and intractable pain, particularly in terminal cancer patients. The company's products are widely utilized across academia and the pharmaceutical industry to create precise lesions in animal models and to validate novel therapeutic targets.